BE2021C505I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2021C505I2 BE2021C505I2 BE2021C505C BE2021C505C BE2021C505I2 BE 2021C505 I2 BE2021C505 I2 BE 2021C505I2 BE 2021C505 C BE2021C505 C BE 2021C505C BE 2021C505 C BE2021C505 C BE 2021C505C BE 2021C505 I2 BE2021C505 I2 BE 2021C505I2
- Authority
- BE
- Belgium
- Prior art keywords
- ides polypeptide
- medicament
- disease
- prevention
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0511769A GB0511769D0 (en) | 2005-06-09 | 2005-06-09 | Treatment |
GB0605781A GB0605781D0 (en) | 2006-03-22 | 2006-03-22 | Treatment |
PCT/EP2006/005454 WO2006131347A2 (fr) | 2005-06-09 | 2006-06-08 | Traitement |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2021C505I2 true BE2021C505I2 (fr) | 2021-05-31 |
Family
ID=36952007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2021C505C BE2021C505I2 (fr) | 2005-06-09 | 2021-02-09 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8133483B2 (fr) |
EP (1) | EP1901773B1 (fr) |
JP (1) | JP5427409B2 (fr) |
CN (1) | CN105770871A (fr) |
AT (1) | ATE548049T1 (fr) |
AU (1) | AU2006256891B2 (fr) |
BE (1) | BE2021C505I2 (fr) |
CA (1) | CA2611646C (fr) |
ES (1) | ES2380950T3 (fr) |
FR (1) | FR21C1004I2 (fr) |
NL (1) | NL301089I2 (fr) |
PL (1) | PL1901773T3 (fr) |
PT (1) | PT1901773E (fr) |
WO (1) | WO2006131347A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134494D1 (de) * | 2000-12-21 | 2008-07-31 | Id Biomedical Corp | Antigene aus streptococcus pyogenes und zugehörige dna-fragmente |
US8691544B2 (en) | 2007-05-04 | 2014-04-08 | Glycorex Transplantation Ab | Material for separation of a biomolecule |
JP5458020B2 (ja) | 2007-12-21 | 2014-04-02 | ロシュ グリクアート アクチェンゲゼルシャフト | 抗体の安定性試験 |
JP5461586B2 (ja) | 2009-02-09 | 2014-04-02 | ロシュ グリクアート アクチェンゲゼルシャフト | 免疫グロブリングリコシル化パターン分析 |
AU2010240486B2 (en) * | 2009-04-22 | 2014-09-18 | Ofir Menashe | Microorganism comprising particles and uses of same |
GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
EP3411389B1 (fr) * | 2016-02-04 | 2021-03-24 | Genovis Ab | Nouvelles protéases streptococciques |
US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
CA3149395A1 (fr) * | 2019-08-01 | 2021-02-04 | Memorial Sloan-Kettering Cancer Center | Cellules pour ameliorer l'immunotherapie et leurs utilisations |
JP2022548197A (ja) | 2019-12-06 | 2022-11-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗vegfタンパク質組成物及びその製造方法 |
GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
EP4215208A1 (fr) * | 2020-09-21 | 2023-07-26 | Shanghai Bao Pharmaceuticals Co., Ltd. | Association pharmaceutique et son utilisation |
CA3195177A1 (fr) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Administration therapeutique de virus adeno-associe de proteine liee a la fukutine (fkrp) pour le traitement de troubles de la dystroglycanopathie comprenant des ceintures 2i (lgmd2i) |
JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン |
EP4079848A1 (fr) | 2021-04-22 | 2022-10-26 | Genovis Ab | Enzyme de clivage d'immunoglobuline |
CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0110779A (pt) * | 2000-05-12 | 2005-01-11 | Beth Israel Hospital | Composições e métodos para adquirir supressão imunológica |
GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
-
2006
- 2006-06-08 AT AT06754207T patent/ATE548049T1/de active
- 2006-06-08 PT PT06754207T patent/PT1901773E/pt unknown
- 2006-06-08 PL PL06754207T patent/PL1901773T3/pl unknown
- 2006-06-08 EP EP06754207A patent/EP1901773B1/fr active Active
- 2006-06-08 CN CN201610049256.0A patent/CN105770871A/zh active Pending
- 2006-06-08 AU AU2006256891A patent/AU2006256891B2/en active Active
- 2006-06-08 US US11/921,770 patent/US8133483B2/en active Active
- 2006-06-08 ES ES06754207T patent/ES2380950T3/es active Active
- 2006-06-08 WO PCT/EP2006/005454 patent/WO2006131347A2/fr active Application Filing
- 2006-06-08 CA CA2611646A patent/CA2611646C/fr active Active
- 2006-06-08 JP JP2008515137A patent/JP5427409B2/ja active Active
-
2021
- 2021-01-14 NL NL301089C patent/NL301089I2/nl unknown
- 2021-02-04 FR FR21C1004C patent/FR21C1004I2/fr active Active
- 2021-02-09 BE BE2021C505C patent/BE2021C505I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
PT1901773E (pt) | 2012-06-06 |
CA2611646A1 (fr) | 2006-12-14 |
WO2006131347A3 (fr) | 2007-05-31 |
AU2006256891A1 (en) | 2006-12-14 |
ATE548049T1 (de) | 2012-03-15 |
PL1901773T3 (pl) | 2012-09-28 |
US20100303781A1 (en) | 2010-12-02 |
CN105770871A (zh) | 2016-07-20 |
NL301089I2 (nl) | 2021-02-04 |
EP1901773A2 (fr) | 2008-03-26 |
CA2611646C (fr) | 2015-08-11 |
US8133483B2 (en) | 2012-03-13 |
JP2008542418A (ja) | 2008-11-27 |
AU2006256891B2 (en) | 2011-08-04 |
EP1901773B1 (fr) | 2012-03-07 |
WO2006131347A2 (fr) | 2006-12-14 |
NL301089I1 (fr) | 2021-01-20 |
JP5427409B2 (ja) | 2014-02-26 |
ES2380950T3 (es) | 2012-05-21 |
FR21C1004I2 (fr) | 2022-01-14 |
FR21C1004I1 (fr) | 2021-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE2021C505I2 (fr) | ||
WO2008071418A3 (fr) | Traitement | |
TW200626171A (en) | Fixed dosing of HER antibodies | |
TW200738270A (en) | Method of treating depression using a TNFα antibody | |
MX341370B (es) | Antagonistas anti - beta7 humanizados y usos para los mismos. | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
MX2009012343A (es) | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. | |
TW200709817A (en) | Platform antibody compositions | |
MY149630A (en) | Antibodies against amyloid-beta peptide | |
WO2006127757A3 (fr) | Fusion interferon-igg | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
MY181969A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
WO2007073497A3 (fr) | Antagonistes des canaux calciques | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
TW200740844A (en) | Novel MAdCAM antibodies | |
HK1125855A1 (en) | Use of oligouronates for treating mucus hyperviscosity | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
WO2006014638A3 (fr) | Anticorps anti-oligomeres reticules de la proteine $g(b)-amyloide | |
MX2011011729A (es) | Anticuerpo anti il-17f y metodos de uso de los mismos. | |
EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
WO2007075852A3 (fr) | Antagonistes du canal calcique | |
MY149492A (en) | Immunoglobulins directed against nogo | |
IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
EA200801180A1 (ru) | Селективные пептидные агонисты рецептора vpac2 |